

**ACTION:** Notification of public meeting and public comment.

**SUMMARY:** Pursuant to the Federal Advisory Committee Act, the U.S. Environmental Protection Agency hereby provides notice that the Board of Scientific Counselors (BOSC) Executive Committee (EC) will host a public meeting at the EPA's Main Campus Facility, 109 T.W. Alexander Drive, Research Triangle Park, North Carolina 27711. The meeting will be held on Wednesday, January 11, 2017 from 9:00 a.m. till 6:00 p.m., Thursday, January 12, 2017 from 8:30 a.m. till 5:00 p.m. and Friday, January 13, 2017 from 8:30 a.m. till 11:00 a.m. All times noted are Eastern Time and are approximate. The primary discussions will focus on the draft reports from the BOSC subcommittees: Air, Climate and Energy, Chemical Safety for Sustainability, Safe and Sustainable Water Resources, and Sustainable and Healthy Communities. The EC will also deliberate on the four ORD Cross-Cutting Research Roadmap Annual Reports: Environmental Justice, Climate Change, Children's Environmental Health, and Nitrogen and Co-pollutant. There will be a public comment period from 10:05 a.m. to 10:20 a.m. Wednesday, January 11, 2017. For information on registering to attend the meeting or to provide public comment, please see the **SUPPLEMENTARY INFORMATION** section.

**DATES:** The BOSC EC meeting will be held on Wednesday, January 11, 2017 from 9:00 a.m. till 6:00 p.m., Thursday, January 12, 2017 from 8:30 a.m. till 5:00 p.m. and Friday, January 13, 2017 from 8:30 a.m. till 11:00 a.m. All times noted are Eastern Time and are approximate.

**FOR FURTHER INFORMATION CONTACT:** Questions or correspondence concerning the meeting should be directed to Tom Tracy, Designated Federal Officer, Environmental Protection Agency, by mail at 1200 Pennsylvania Avenue NW., (MC 8104 R), Washington, DC 20460; by telephone at 202-564-6518; fax at 202-565-2911; or via email at [tracy.tom@epa.gov](mailto:tracy.tom@epa.gov).

**SUPPLEMENTARY INFORMATION:** The Charter of the BOSC states that the advisory committee shall provide independent advice to the Administrator on technical and management aspects of the ORD's research program. Additional information about the BOSC is available at: <http://www2.epa.gov/bosc>.

**Registration:** In order to attend the meeting, you must register at the following site: <https://www.eventbrite.com/e/us-epa-2017->

[bosc-executive-committee-public-meeting-registration-30037268278](https://www.eventbrite.com/e/us-epa-2017-bosc-executive-committee-public-meeting-registration-30037268278). Once you have completed the online registration, you will be contacted and provided with the meeting information. In-person participant registration will close on January 3, 2017. Virtual participant registration will close on January 9, 2017.

**Oral Statements:** Members of the public who wish to provide oral comment during the meeting must preregister. Individuals or groups making remarks during the public comment period will be limited to five (5) minutes. To accommodate the number of people who want to address the BOSC EC, only one representative of a particular community, organization, or group will be allowed to speak.

**Written Statements:** Written comments for the public meeting must be received by Monday, January 9, 2017, and will be included in the materials distributed to the BOSC EC prior to the meeting. Written comments should be sent to Tom Tracy, Environmental Protection Agency, via email at [tracy.tom@epa.gov](mailto:tracy.tom@epa.gov) or by mail to 1200 Pennsylvania Avenue NW., (MC 8104 R), Washington, DC 20460, or submitted through [regulations.gov](http://regulations.gov), Docket ID No. EPA-HQ-ORD-2015-0765. Members of the public should be aware that their personal contact information, if included in any written comments, may be posted online at [regulations.gov](http://regulations.gov).

**Information about Services for Individuals with Disabilities:** For information about access or services for individuals with disabilities, please contact Tom Tracy, at 202-564-6518 or via email at [tracy.tom@epa.gov](mailto:tracy.tom@epa.gov). To request special accommodations, please contact Tom Tracy no later than August 19, 2016, to give the Environmental Protection Agency sufficient time to process your request. All requests should be sent to the address, email, or phone number listed in the **FOR FURTHER INFORMATION** section above.

Dated: December 16, 2016.

**Fred S. Hauchman**

*Director, Office of Science Policy.*

[FR Doc. 2016-31825 Filed 12-30-16; 8:45 am]

**BILLING CODE 6560-50-P**

## FEDERAL MINE SAFETY AND HEALTH REVIEW COMMISSION

[BAC 6735-01]

### Sunshine Act Meeting

December 29, 2016.

**TIME AND DATE:** 10:00 a.m., Friday, February 3, 2017.

**PLACE:** The Richard V. Backley Hearing Room, Room 511N, 1331 Pennsylvania Avenue NW., Washington, DC 20004 (enter from F Street entrance).

**STATUS:** Open.

**MATTERS TO BE CONSIDERED:** The Commission will consider and act upon the following in open session: *Secretary of Labor on behalf of Greathouse, et al. v. Monongalia County Coal Company, et al.*, Docket Nos. WEVA 2015-904-D, et al. (Issues include whether the Judge erred in ruling that certain bonus plans instituted by the operators interfered with miners' rights under the Mine Act.)

Any person attending this meeting who requires special accessibility features and/or auxiliary aids, such as sign language interpreters, must inform the Commission in advance of those needs. Subject to 29 CFR 2706.150(a)(3) and § 2706.160(d).

### CONTACT PERSON FOR MORE INFO:

Emogene Johnson (202) 434-9935/(202) 708-9300 for TDD Relay/1-800-877-8339 for toll free.

### PHONE NUMBER FOR LISTENING TO

**ARGUMENT:** 1 (866) 867-4769; Passcode: 129-339.

**Sarah L. Stewart,**

*Deputy General Counsel.*

[FR Doc. 2016-31879 Filed 12-29-16; 11:15 am]

**BILLING CODE 6735-01-P**

## FEDERAL MINE SAFETY AND HEALTH REVIEW COMMISSION

[BAC 6735-01]

### Sunshine Act Meeting

December 29, 2016.

**TIME AND DATE:** 10:00 a.m., Thursday, February 2, 2017.

**PLACE:** The Richard V. Backley Hearing Room, Room 511N, 1331 Pennsylvania Avenue NW., Washington, DC 20004 (enter from F Street entrance).

**STATUS:** Open.

**MATTERS TO BE CONSIDERED:** The Commission will hear oral argument in the matter *Secretary of Labor on behalf of Greathouse, et al. v. Monongalia County Coal Company, et al.*, Docket Nos. WEVA 2015-904-D, et al. (Issues include whether the Judge erred in ruling that certain bonus plans instituted by the operators interfered with miners' rights under the Mine Act.)

Any person attending this oral argument who requires special accessibility features and/or auxiliary aids, such as sign language interpreters, must inform the Commission in advance of those needs. Subject to 29 CFR 2706.150(a)(3) and § 2706.160(d).

**CONTACT PERSON FOR MORE INFO:**

Emogene Johnson (202) 434-9935/(202) 708-9300 for TDD Relay/1-800-877-8339 for toll free.

**PHONE NUMBER FOR LISTENING TO**

**ARGUMENT:** 1 (866) 867-4769; Passcode: 129-339.

**Sarah L. Stewart,**

*Deputy General Counsel.*

[FR Doc. 2016-31878 Filed 12-29-16; 11:15 am]

**BILLING CODE 6735-01-P**

**FEDERAL TRADE COMMISSION**

[File No. 161 0126]

**Abbott Laboratories and St. Jude Medical, Inc.; Analysis to Aid Public Comment**

**AGENCY:** Federal Trade Commission.

**ACTION:** Proposed Consent Agreement.

**SUMMARY:** The consent agreement in this matter settles alleged violations of federal law prohibiting unfair methods of competition. The attached Analysis to Aid Public Comment describes both the allegations in the complaint and the terms of the consent orders—embodied in the consent agreement—that would settle these allegations.

**DATES:** Comments must be received on or before January 26, 2017.

**ADDRESSES:** Interested parties may file a comment at <https://ftcpublic.commentworks.com/ftc/abbottjudeconsent> online or on paper,

by following the instructions in the Request for Comment part of the **SUPPLEMENTARY INFORMATION** section below. Write “In the Matter of St. Jude Medical, Inc./Abbott Laboratories, File No. 161 0126- Consent Agreement” on your comment and file your comment online at <https://ftcpublic.commentworks.com/ftc/abbottjudeconsent> by following the instructions on the web-based form. If you prefer to file your comment on paper, write “In the Matter of St. Jude Medical, Inc./Abbott Laboratories, File No. 161 0126—Consent Agreement” on your comment and on the envelope, and mail your comment to the following address: Federal Trade Commission, Office of the Secretary, 600 Pennsylvania Avenue NW., Suite CC-5610 (Annex D), Washington, DC 20580, or deliver your comment to the following address: Federal Trade Commission, Office of the Secretary, Constitution Center, 400 7th Street, SW., 5th Floor, Suite 5610 (Annex D), Washington, DC 20024.

**FOR FURTHER INFORMATION CONTACT:**

Jordan Andrew (202-326-3678), Bureau

of Competition, 600 Pennsylvania Avenue NW., Washington, DC 20580.

**SUPPLEMENTARY INFORMATION:** Pursuant to Section 6(f) of the Federal Trade Commission Act, 15 U.S.C. 46(f), and FTC Rule 2.34, 16 CFR 2.34, notice is hereby given that the above-captioned consent agreement containing consent orders to cease and desist, having been filed with and accepted, subject to final approval, by the Commission, has been placed on the public record for a period of thirty (30) days. The following Analysis to Aid Public Comment describes the terms of the consent agreement, and the allegations in the complaint. An electronic copy of the full text of the consent agreement package can be obtained from the FTC Home Page (for December 27, 2016), on the World Wide Web, at <http://www.ftc.gov/os/actions.shtm>.

You can file a comment online or on paper. For the Commission to consider your comment, we must receive it on or before January 26, 2017. Write “In the Matter of St. Jude Medical, Inc./Abbott Laboratories, File No. 161 0126—Consent Agreement” on your comment. Your comment—including your name and your state—will be placed on the public record of this proceeding, including, to the extent practicable, on the public Commission Web site, at <http://www.ftc.gov/os/publiccomments.shtm>. As a matter of discretion, the Commission tries to remove individuals’ home contact information from comments before placing them on the Commission Web site.

Because your comment will be made public, you are solely responsible for making sure that your comment does not include any sensitive personal information, like anyone’s Social Security number, date of birth, driver’s license number or other state identification number or foreign country equivalent, passport number, financial account number, or credit or debit card number. You are also solely responsible for making sure that your comment does not include any sensitive health information, like medical records or other individually identifiable health information. In addition, do not include any “[t]rade secret or any commercial or financial information which . . . is privileged or confidential,” as discussed in Section 6(f) of the FTC Act, 15 U.S.C. 46(f), and FTC Rule 4.10(a)(2), 16 CFR 4.10(a)(2). In particular, do not include competitively sensitive information such as costs, sales statistics, inventories, formulas, patterns, devices, manufacturing processes, or customer names.

If you want the Commission to give your comment confidential treatment, you must file it in paper form, with a request for confidential treatment, and you have to follow the procedure explained in FTC Rule 4.9(c), 16 CFR 4.9(c).<sup>1</sup> Your comment will be kept confidential only if the FTC General Counsel, in his or her sole discretion, grants your request in accordance with the law and the public interest.

Postal mail addressed to the Commission is subject to delay due to heightened security screening. As a result, we encourage you to submit your comments online. To make sure that the Commission considers your online comment, you must file it at <https://ftcpublic.commentworks.com/ftc/abbottjudeconsent> by following the instructions on the web-based form. If this Notice appears at <http://www.regulations.gov#!/home>, you also may file a comment through that Web site.

If you file your comment on paper, write “In the Matter of St. Jude Medical, Inc./Abbott Laboratories, File No. 161 0126- Consent Agreement” on your comment and on the envelope, and mail your comment to the following address: Federal Trade Commission, Office of the Secretary, 600 Pennsylvania Avenue NW., Suite CC-5610 (Annex D), Washington, DC 20580, or deliver your comment to the following address: Federal Trade Commission, Office of the Secretary, Constitution Center, 400 7th Street SW., 5th Floor, Suite 5610 (Annex D), Washington, DC. If possible, submit your paper comment to the Commission by courier or overnight service.

Visit the Commission Web site at <http://www.ftc.gov> to read this Notice and the news release describing it. The FTC Act and other laws that the Commission administers permit the collection of public comments to consider and use in this proceeding as appropriate. The Commission will consider all timely and responsive public comments that it receives on or before January 26, 2017. You can find more information, including routine uses permitted by the Privacy Act, in the Commission’s privacy policy, at <http://www.ftc.gov/ftc/privacy.htm>.

<sup>1</sup> In particular, the written request for confidential treatment that accompanies the comment must include the factual and legal basis for the request, and must identify the specific portions of the comment to be withheld from the public record. See FTC Rule 4.9(c), 16 CFR 4.9(c).